Public Employees Retirement System of Ohio Has $50.77 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Public Employees Retirement System of Ohio lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 19.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 897,664 shares of the biopharmaceutical company's stock after selling 212,431 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Bristol-Myers Squibb were worth $50,772,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Pacific Point Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth approximately $579,000. GTS Securities LLC grew its holdings in Bristol-Myers Squibb by 127.9% during the 4th quarter. GTS Securities LLC now owns 19,911 shares of the biopharmaceutical company's stock worth $1,126,000 after acquiring an additional 91,354 shares in the last quarter. Fourth Dimension Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $48,000. Vise Technologies Inc. raised its stake in shares of Bristol-Myers Squibb by 34.9% in the 4th quarter. Vise Technologies Inc. now owns 44,870 shares of the biopharmaceutical company's stock valued at $2,538,000 after purchasing an additional 11,615 shares in the last quarter. Finally, JT Stratford LLC raised its stake in shares of Bristol-Myers Squibb by 215.8% in the 4th quarter. JT Stratford LLC now owns 33,554 shares of the biopharmaceutical company's stock valued at $1,898,000 after purchasing an additional 22,929 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 0.7%

BMY traded down $0.32 during trading on Wednesday, reaching $46.57. The company had a trading volume of 4,468,850 shares, compared to its average volume of 13,116,114. The firm's 50-day simple moving average is $51.26 and its 200 day simple moving average is $55.60. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market cap of $94.77 billion, a price-to-earnings ratio of -10.54, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion for the quarter, compared to the consensus estimate of $10.77 billion. During the same quarter in the previous year, the company posted ($4.40) earnings per share. Bristol-Myers Squibb's revenue for the quarter was down 5.6% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were paid a dividend of $0.62 per share. The ex-dividend date was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.33%. Bristol-Myers Squibb's dividend payout ratio (DPR) is 92.88%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of the stock in a transaction on Friday, April 25th. The shares were purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now directly owns 83,513 shares of the company's stock, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.09% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on BMY shares. Citigroup upped their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Argus raised Bristol-Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price for the company. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Wells Fargo & Company increased their price objective on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.